PROSTVAC~——一种前列腺癌治疗性疫苗的研究进展

Research progress toward a therapeutic vaccine against prostate cancer:PROSTVAC~

前列腺癌已经成为全世界男性最常见的癌症之一,目前临床采用的手术、化疗等传统治疗手段存在前列腺特异性抗原(Prostate specific antigen,PSA)复发、癌细胞转移等缺陷。PROSTVAC~疫苗的研发为前列腺癌的治疗提供了一种新的思路。PROSTVAC~是一种由导入了PSA和三合一共刺激分子(Triad of costimulatory molecules,TRICOM)基因的重组痘苗病毒和重组鸡痘病毒组成的疫苗。临床前研究和I期临床研究分别证明了PROSTVAC~的免疫机理和安全性、耐受性;Ⅱ期临床研究证明了PROSTVAC~的有效性和耐受性,能够延长前列腺癌患者的总生存期(Overall survival,OS)达9个月左右;PROSTVAC~的Ⅲ期临床研究目前正在进行中,研究结果预计于2017年初发布。PROSTVAC~作为一种治疗前列腺癌的新型免疫疗法具有很好的前景。

Prostate cancer is one of the most common cancers in men all over the world. Currently, con- ventional treatments of prostate cancer, such as surgery and chemotherapy, have many disadvantages in- cluding prostate specific antigen （PSA） recurrence and cancer metastasis. The development of a vaecine- PROSTVAC-provides a new solution for the treatment of prostate cancer. PROSTVAC consists of recombinant vaccinia virus and recombinant fowlpox virus, and contains PSA and triad of eo-stimulatory molecules （TRICOM） genes. Preclinieal trials and phase I clinical trials demonstrated its immunologic mechanisms and its safety and tolerance. Phase Ⅱ clinical trials demonstrated its effectiveness and tolerance, as the vaccine could extend overall survival （OS） of prostate cancer patients for as long as 9 months. A phase Ⅲ clinical trial of PROSTVAC is underway, and results are expected to be issued in early 2017. As a new immunotherapy, PROSTVAC has a good prospect for treatment of prostate cancer.